I’m excited to share a deeper look into my professional journey in oncology research, clinical development, and regulatory science. Over the past 30+ years, I’ve had the opportunity to work across global biopharma organizations, advisory boards, and academic institutions, all focused on advancing patient-centered innovation. Here is my biography.

I’m pleased to share a comprehensive biography that reflects my professional journey across clinical medicine, public health, and biopharmaceutical leadership. It highlights the experiences, values, and strategic insights that have shaped my four decades of work in advancing healthcare solutions and supporting the teams and organizations I’ve been privileged to serve.

I’m excited to share my professional biography, which highlights my journey through clinical research leadership, operational transformation, and mentorship within the pharmaceutical and biotechnology industries. My passion lies in creating scalable systems, empowering teams, and advancing the science that improves patient lives.

Driving strategic innovation in healthcare requires more than adopting new technologies—it demands a cultural and operational shift that unites people, processes, and technology toward a shared vision of improvement. By cultivating a culture that encourages experimentation and cross-functional collaboration, leveraging data-driven insights to inform smarter decisions, and aligning new initiatives with best practices and regulatory standards, healthcare leaders can foster innovation that is both creative and compliant. When innovation is strategically embedded into every layer of clinical research, organizations can accelerate development, enhance patient outcomes, and achieve sustainable, transformative growth.

Dr. Trudy Vanhove is a seasoned biopharmaceutical executive and venture partner with nearly 30 years of experience leading drug development, regulatory strategy, and corporate growth across biotech and pharmaceutical companies. She has played a pivotal role in launching multiple FDA- and EMA-approved therapies and has a strong track record in building high-performing teams, driving strategic partnerships, and supporting financing efforts. Fluent in several languages and with extensive international experience, Dr. Vanhove brings a unique global perspective and a deep scientific and business acumen to board roles and investment opportunities in the biotech sector.

Dr. Steven R. Goldstein is an internationally renowned expert in gynecologic ultrasound and women’s midlife health. As a tenured Professor of Obstetrics and Gynecology at NYU Grossman School of Medicine, his career spans over four decades of pioneering research, clinical innovation, and global education. Dr. Goldstein has served as President of the American Institute of Ultrasound in Medicine, the North American Menopause Society, and the International Menopause Society, reflecting his influential leadership across multiple disciplines. A prolific author and sought-after speaker, he has transformed the standards of care for menopause, osteoporosis, and abnormal uterine bleeding, while mentoring generations of physicians and shaping the future of women's healthcare worldwide.

I’m a seasoned clinical research professional with over two decades of experience supporting and leading clinical trials across all phases and therapeutic areas. My journey has taken me through top pharmaceutical organizations like Bristol Myers Squibb, GSK, Karuna Therapeutics, and AstraZeneca, where I’ve specialized in clinical operations, regulatory compliance, and team development. I’m passionate about building efficient systems, mentoring others, and contributing to work that ultimately improves patient lives.

Susan Essumang is a seasoned clinical operations executive who merges scientific rigor with strategic leadership to drive high-impact pharmaceutical and biotech programs. Known for her patient-centric approach, Susan has led the development and regulatory success of globally recognized treatments, including Victoza®, Ozempic®, and Wegovy®, delivering billions in projected revenue. Her ability to align enterprise objectives with operational excellence has resulted in accelerated trial timelines, significant cost savings, and flawless regulatory inspections. With deep therapeutic expertise, a foundation in neuroscience and healthcare administration, and a commitment to innovation, Susan continues to shape the future of clinical research through data-driven insights and strategic execution.

Dr. Kashinath Yadalam is a seasoned psychiatrist and clinical research leader with over 40 years of experience advancing treatments for psychiatric and neurological disorders. As Owner and Medical Director of Lake Charles Clinical Trials, he has built a respected institution known for its high standards in ethical, safe, and innovative clinical research. A Distinguished Life Fellow of the American Psychiatric Association and a Certified Physician Investigator, Dr. Yadalam has collaborated with pharmaceutical companies, academic institutions, and regulatory bodies to design and oversee groundbreaking trials in psychopharmacology. His career reflects a lifelong commitment to improving mental health care through scientific rigor, compassionate practice, and academic excellence.

After more than 30 years immersed in the world of cell and gene therapy, I've had the privilege to lead, innovate, and mentor across academic, clinical, and industry landscapes. From cleanroom design to regulatory submissions and teaching future leaders, my journey has been defined by purpose and progress. Here is my biography.

I'm excited to share my executive biography, which reflects over two decades of work in vaccine innovation, strategic investment, and scientific leadership across global biopharmaceutical landscapes. This journey has been rooted in a passion for transforming complex science into real-world solutions.

Dr. Hassan Razvi is a globally respected healthcare innovator and urological surgeon with over three decades of experience advancing medical research, device development, and clinical excellence. Known for his leadership in early-stage product innovation through to clinical trials, he has contributed extensively to the global medical community through board service, international collaboration, and impactful communication. Dr. Razvi's ability to translate complex clinical insights into strategic direction makes him a valuable advisor to companies aiming to grow and innovate in the healthcare, pharmaceutical, and medical device industries.

Dr. Michael E. Kuligowski, MD, PhD, MBA, is a globally recognized physician-executive with over four decades of leadership in dermatology, clinical development, and pharmaceutical strategy. With a distinguished career spanning Europe and the United States, he has led the development and approval of numerous dermatologic therapies, including Opzelura® for atopic dermatitis and vitiligo. Known for his scientific rigor, strategic foresight, and collaborative leadership, Dr. Kuligowski continues to influence the future of dermatologic innovation through executive roles, advisory board appointments, and pro-bono consulting in the life sciences sector.

Dr. Larrye Ellis Loss, PharmD, MBA, is a global pharmaceutical executive and consultant with over 40 years of experience leading clinical development, medical affairs, and strategic operations across the life sciences industry. With a distinguished career at AstraZeneca and current advisory work through his own consultancy, Larrye brings deep expertise in drug development, regulatory strategy, and cross-functional leadership. He is known for his integrity, global perspective, and commitment to mentoring the next generation of healthcare professionals. Passionate about service, he also dedicates his time to nonprofit leadership and disaster relief with the American Red Cross.

Mary Hames is a seasoned Medical Affairs executive with a proven track record of leading high-performing teams and delivering strategic impact across rare disease, diagnostics, and oncology. With a foundation in biochemical genetics and over a decade of industry experience, she has played pivotal roles in clinical operations, launch preparedness, and cross-functional leadership. Known for her ability to navigate complex medical landscapes, Mary has successfully built and led medical teams, advanced companion diagnostics, and driven field strategy across multiple therapeutic areas. Her leadership is marked by scientific rigor, operational excellence, and a deep commitment to improving outcomes for patients with rare and life-threatening conditions.

As a physician-scientist and biotech executive, I have dedicated my career to bridging the gap between groundbreaking medical research and commercial success. From securing multimillion-dollar funding to leading strategic M&A deals, my passion lies in driving healthcare innovation that delivers real-world impact. Here is my biography.